← Back to screener

STANDARD BIOTOOLS INC. LAB

Rank #1840 · Nasdaq · $0.2B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
40.9
P/E
-3.2
P/B
-2.92
ROE
91.6%
Op. Margin
-72.0%
Debt Ratio
-173%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -3.2x, P/B -2.92x. Ranks in the top 96% of the universe.

Profitability ★★★☆☆
Average

ROE 91.6%. Ranks in the top 46% of the universe.

Safety ★★★★★
Excellent

Debt ratio -173%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆
Good

Revenue growth of 8.6% year over year. Ranks in the top 38% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$-0.2B-71.0-19
2012$0.0B$-0.0B$-0.0B$-0.2B-43.4-13
2013$0.0B$-0.0B$-0.0B$-0.2B-43.3-7
2014$0.1B$-0.0B$-0.0B$0.1B-34.536
2015$0.1B$-0.0B$-0.0B$0.1B-26.2255
2016$0.1B$-0.1B$-0.1B$0.1B-44.5265
2017$0.1B$-0.1B$-0.1B$0.2B-43.7168
2018$0.1B$-0.1B$-0.1B$0.1B-70.1223
2019$0.1B$-0.1B$-0.1B$0.1B-57.3435
2020$0.1B$-0.0B$-0.1B$0.0B-42.6359
2021$0.1B$-0.1B$-0.1B$0.1B-44.2258
2022$0.1B$-0.1B$-0.1B$0.1B-51.7130
2023$0.1B$-0.1B$-0.2B$0.1B-118.6170
2024$0.1B$-0.1B$-0.2B$0.1B-118.6169
2025$0.1B$-0.1B$-0.1B$-0.1B-72.0-173

← See the full screener